Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) has launched a new Health Coaching service on questhealth.com through Pack Health®. The service connects individuals with board-certified health advisers for personalized support in areas including general health, weight management, chronic kidney disease, type 2 diabetes, and high cholesterol. The program offers two packages: a 4-session package for $225 and a 6-session package for $275, including one-on-one virtual coaching sessions, regular communication, a welcome kit, and digital content. Customers can integrate their Quest lab results with coaching for a more tailored experience.
Parker Family Health Center (PFHC) in Red Bank, NJ, celebrated its facility expansion with a ribbon-cutting ceremony attended by Quest Diagnostics executives. The renovation includes new exam rooms, conference spaces, private patient areas, and a dedicated phlebotomy room for telehealth services. Quest Diagnostics provides no-cost lab testing through its Quest for Health Equity (Q4HE) initiative.
PFHC has operated for over 23 years, recording nearly 190,000 patient visits, and serves uninsured or underinsured Monmouth County residents. The center maintained operations during its 18-month renovation project and is supported by over 130 volunteers including doctors, nurses, interpreters, and administrative staff.
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.75 per share. The dividend will be payable on January 29, 2025 to shareholders of record as of January 14, 2025. This announcement demonstrates the company's continued commitment to returning value to shareholders through regular dividend payments.
A former corrections worker shares her journey joining Quest Diagnostics as a logistics driver between Longview, Texas and Shreveport, Louisiana. The employee highlights the independence of her role, the importance of logistics in patient care, and the supportive work environment at Quest. She appreciates the professional atmosphere, knowledge sharing among experienced colleagues, and the opportunity to coordinate social activities between hubs.
Quest Diagnostics through its philanthropic initiative Quest for Health Equity partnered with Choose Healthy Life to address health disparities in Black and brown communities. The collaboration emerged following observations of disproportionate COVID-19 impact on underserved populations. Quest provided COVID-19 testing support and funding to help bridge healthcare gaps. Rev. Kimberly L. Williams, Choose Healthy Life's executive director, highlighted that pre-existing conditions contributed to higher mortality rates in these communities.
Quest Diagnostics highlights the career progression of Jessie Hutchens Maxwell, who evolved from a manual sample processor to a Bio-Analytical Instrument Technician over nearly 7 years. Starting as a temp at Oxford Immunotec before Quest's acquisition, Jessie advanced to the project team, helping develop automated processing systems. In her current role, she maintains and troubleshoots essential automated equipment. The journey showcases Quest's support for employee growth through tuition reimbursement and leadership encouragement, emphasizing the company's commitment to continuous improvement and employee development.
Martha Baer shares her 31-year journey with Quest Diagnostics, starting in 1993 as a courier at Nichols Institute. Through various company transitions and acquisitions, including Corning Clinical Laboratories and Smith Kline Beecham Clinical Laboratories, she experienced significant professional growth. The acquisition of Smith Kline Beecham marked a major expansion, moving operations to a larger facility in Kansas City, MO. Baer progressed from courier to stock clerk, Group Lead, and eventually to her current role as Network Planner and Route Optimization Specialist for the Greater Midwest Region. Her career particularly advanced during the LabOne acquisition in Lenexa, KS, where she took on increased responsibilities.
Quest Diagnostics (NYSE: DGX) has secured CDC contracts to develop tests for avian influenza and Oropouche virus. The company will introduce a molecular test for avian influenza A H5 virus detection by month-end at its San Juan Capistrano laboratory. The agreements support national preparedness by ensuring commercial laboratory capacity can supplement public health labs during potential outbreaks.
The new H5 test will be available with a prescription for clinical purposes, using respiratory or conjunctiva specimens. While avian influenza is currently widespread in wild birds and causing outbreaks in U.S. poultry and dairy cows, the public health risk remains low. The contracts include funding for maintaining testing readiness and necessary supplies.
Quest Diagnostics (NYSE: DGX) reported strong third quarter 2024 financial results, with revenues of $2.49 billion, up 8.5% from 2023. The company's performance was driven by new customer wins, expanded business, and recent acquisitions. Reported diluted EPS increased 1.5% to $1.99, while adjusted diluted EPS rose 3.6% to $2.30.
Quest has updated its full-year 2024 guidance, now expecting revenues between $9.80 billion and $9.85 billion. Reported diluted EPS is projected to be between $7.60 and $7.70, with adjusted diluted EPS between $8.85 and $8.95. The guidance reflects recent acquisitions and the impact of Hurricane Milton in Q4, which is expected to negatively affect net revenues by approximately $15 million and EPS by about 8 cents.
Adam Slough shares his 29-year journey with Quest Diagnostics in St. Louis, Missouri. Starting as a Specimen Processor in 1995, he progressed to become a driver for the Logistics team, recently winning an employee recognition award. His experience includes roles as an independent courier and swing driver, serving parts of 4 states. Adam highlights Quest's role in his personal growth and mentions his family's involvement with the company, including his aunt, mother, and wife.
Adam emphasizes the importance of understanding how individual roles support the bigger picture at Quest, focusing on patient care. He expresses gratitude for the support he's received and hopes to continue serving for many more years. His story underscores Quest Diagnostics' commitment to employee development and patient-centered service.